Merck: A Speed Bump For Keytruda?
June 13, 2017 at 09:18 AM EDT
Shares of Merck are falling after the drug maker paused two enrollment in two big studies testing its cancer drug Keytruda as a treatment for multiple myleoma.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|